SEOUL, Jan. 31 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Shares finished higher Friday as U.S. President Donald Trump's call for interest rate cuts boosted appetite for risky assets.

South Korean stocks finished higher on Friday as US President Donald Trump's call for interest rate cuts boosted appetite for ...

South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small ...

Teva and Celltrion’s attempt to muscle in on the multi-billion dollar US cancer and inflammatory disease drug market has hit a setback after the FDA rejected two key biosimilars because of ...